Thyrocare Technologies ke Q2 FY27 results aa gaye hain. Revenue **₹270.81 Cr** tak pahunch gaya hai, lekin profit gir kar **₹15.22 Cr** ho gaya hai. Iske peeche ka main reason hai unki subsidiary, Nueclear Healthcare, mein hua **₹44.98 Cr** ka loss.
Revenue badha, Profit kyun gira?
Thyrocare ka top-line performance kaafi strong raha hai, revenue ₹270.81 Crore tak chala gaya hai, jo last year ₹216.53 Crore tha. Lekin, bottom-line par impact isliye aaya kyunki company ko apne subsidiary, Nueclear Healthcare Limited (NHL), par ₹44.98 Crore ka impairment loss book karna pada. Is wajah se profit ₹47.81 Crore se ghat kar sirf ₹15.22 Crore reh gaya.
Nueclear Healthcare deal ka status
Company ab apne balance sheet ko clean karne ke liye NHL ko bechne wali hai. Ye deal ₹141.40 Crore ki hai, jisme cash aur Compulsorily Convertible Preference Shares dono shamil hain. Ab sab kuch shareholders ke haath mein hai, jinhe October 29, 2026 tak vote karna hai.
Core business ka kya haal hai?
Diagnostics business ab bhi company ki asli taqat hai, jisne ₹256.74 Crore ka revenue generate kiya hai. Imaging services se ₹13.55 Crore aaye hain. Investors ko ab bas is deal ke complete hone ka intezaar hai, kyunki isi se pata chalega ki aage margins kaise improve honge.